✦ LIBER ✦

Clinical and Immunological Characteristics of Patients With Serologic Progression of Prostate Cancer Achieving Long-Term Disease Control With Granulocyte-Macrophage Colony-Stimulating Factor

✍ Scribed by Rini, Brian I.; Fong, Lawrence; Weinberg, Vivian; Kavanaugh, Brian; Small, Eric J.

Book ID: 123305543
Publisher: Lippincott Williams and Wilkins
Year: 2006
Tongue: English
Weight: 330 KB
Volume: 175
Category: Article
ISSN: 0022-5347
DOI: 10.1016/S0022-5347(06)00261-8

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Re: Clinical and Immunological Character

Re: Clinical and Immunological Characteristics of Patients With Serologic Progression of Prostate Cancer Achieving Long-Term Disease Control With Granulocyte-Macrophage Colony-Stimulating Factor

✍ Brú, Antonio 📂 Article 📅 2007 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 42 KB

Effect of recombinant human granulocyte

Effect of recombinant human granulocyte macrophage-colony stimulating factor in long-term marrow cultures from patients with aplastic anemia

✍ Mart�nez-Jaramillo, Guadalupe; G�mez-Morales, Enrique; Mayani, Hector 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 208 KB 👁 2 views

The hematopoietic system in patients with aplastic anemia (AA) shows both quantitative and qualitative deficiencies, i.e., reduced numbers of hematopoietic progenitor cells (HPC) and impaired HPC proliferation in long-term marrow cultures (LTMC). Since recombinant human granulocyte macrophage-colony

Sequential interleukin 3 and granulocyte

Sequential interleukin 3 and granulocyte-macrophage–colony stimulating factor therapy in patients with bone marrow failure with long-term follow-up of responses

✍ Hillary H. Wu; Moshe Talpaz; Richard E. Champlin; Susan R. Pilat; Razelle Kurzro 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 138 KB

## Background: Interleukin-3 (il-3) and granulocyte-macrophage-colony stimulating factor (gm-csf) have synergistic, hematopoietic growth-promoting activity in preclinical studies. because of the paucity of effective therapies for patients with chronic bone marrow failure states, the authors studied

Phase II trial of anti-idiotypic p53 pep

Phase II trial of anti-idiotypic p53 peptides (Pentrys) plus granulocyte-macrophage colony-stimulating factor in patients with hormone-refractory prostate cancer

✍ Ian D DAVIS; Guy TONER; Adam BROAD; Louise M CAMPANO; Mark ROSENTHAL 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 171 KB

113 POSTER Phase II trial to assess the

113 POSTER Phase II trial to assess the activity of MVA5T4 (Trovax®) alone versus MVA5T4 plus granulocyte macrophage colony-stimulating factor (GM-CSF) in patients (pts) with progressive hormone refractory prostate cancer (HRPC)

✍ R. Amato; M. Karediy; A. Cao; M. Khan; S. Naylor; M. McDonald; R. Harrop; W. Shi 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 61 KB

Granulocyte-colony stimulating factor in

Granulocyte-colony stimulating factor in the prevention of postoperative infectious complications and sub-optimal recovery from operation in patients with colorectal cancer and increased preoperative risk (ASA 3 and 4)¶ Protocol of a controlled clinical trial developed by consensus of an international study group¶ Part one: rationale and hypothesis

✍ W. Lorenz, B. Stinner, A. Bauhofer, M. Rothmund, I. Celik, A. Fingerhut, M. Koll 📂 Article 📅 2001 🏛 SP Birkhäuser Verlag Basel 🌐 English ⚖ 87 KB